```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 25   CA/CAPLUS - Russian Agency for Patents and Trademarks
                   (ROSPATENT) added to list of core patent offices covered
 NEWS  4  FEB 28   PATDPAFULL - New display fields provide for legal status
                   data from INPADOC
 NEWS  5  FEB 28   BABS - Current-awareness alerts (SDIs) available
 NEWS  6  FEB 28   MEDLINE/LMEDLINE reloaded
 NEWS  7  MAR 02   GBFULL: New full-text patent database on STN
 NEWS  8  MAR 03   REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS  9  MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS  10 MAR 22   KOREAPAT now updated monthly; patent information enhanced
 NEWS  11 MAR 22   Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS  12 MAR 22   PATDPASPC - New patent database available
 NEWS  13 MAR 22   REGISTRY/ZREGISTRY enhanced with experimental property tags
 NEWS  14 APR 04   EPFULL enhanced with additional patent information and new
                   fields
 NEWS  15 APR 04   EMBASE - Database reloaded and enhanced
 NEWS  16 APR 18   New CAS Information Use Policies available online

 NEWS EXPRESS  JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:42:54 ON 20 APR 2005

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst, biosis
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'MEDLINE' ENTERED AT 16:43:22 ON 20 APR 2005

FILE 'USPATFULL' ENTERED AT 16:43:22 ON 20 APR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE 'DGENE' ENTERED AT 16:43:22 ON 20 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 16:43:22 ON 20 APR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:43:22 ON 20 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'FSTA' ENTERED AT 16:43:22 ON 20 APR 2005
COPYRIGHT (C) 2005 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 16:43:22 ON 20 APR 2005
COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 16:43:22 ON 20 APR 2005
Copyright (c) 2005 The Thomson Corporation

=> s alpha lactoalbumin
   4 FILES SEARCHED...
L1   223 ALPHA LACTOALBUMIN

=> s alpha lactalbumin
L2   9177 ALPHA LACTALBUMIN

=> s l2 and oligomeric form
L3   14 L2 AND OLIGOMERIC FORM

=> d l3 ti abs ibib tot

L3   ANSWER 1 OF 14 USPATFULL on STN
TI   Therapeutic agents
AB   An agent comprising a protein complex comprising an **oligomeric form** of .**alpha**.-**lactalbumin** (MAL) and a
       further reagent which is combined with MAL such that it is carried into
       the nucleoplasm of cells which are susceptible to MAL. Agents of the
       type, where the further reagent is a therapeutic or labelling reagent,
       can be used in diagnosis and therapy in particular of cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:270008 USPATFULL
TITLE: Therapeutic agents
INVENTOR(S):   Svanborg, Catharina, University of Lund Department of
                         Laboratory Medicine, Division of Clinical Immunology,
                         Solvegatan 23, S-223 62 Lund, SWEDEN
                         Hakansson, Per Anders, Flormans gatan 2A, S-223 54
                         Lund, SWEDEN

                              NUMBER   KIND   DATE
                         ---------------- ------ --------
PATENT INFORMATION: US 6808930   B1   20041026
                         WO 9927967   19990610
APPLICATION INFO.:   US 2000-555270   20000830 (9)
                         WO 1998-IB1920   19981123

                               NUMBER   DATE
                         ------------------ --------
PRIORITY INFORMATION: GB 1997-25126   19971127
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Caputa, Anthony C.
ASSISTANT EXAMINER: Holleran, Anne L.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1034

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 14 USPATFULL on STN

TI Pharmaceutical proteins, human therapeutics, human serum albumin, insulin, native cholera toxic b submitted on transgenic plastids

AB Transgenic chloroplast technology could provide a viable solution to the production of Insulin-like Growth Factor I (IGF-I), Human Serum Albumin (HSA), or interferons (IFN) because of hyper-expression capabilities, ability to fold and process eukaryotic proteins with disulfide bridges (thereby eliminating the need for expensive post-purification processing). Tobacco is an ideal choice because of its large biomass, ease of scale-up (million seeds per plant), genetic manipulation and impending need to explore alternate uses for this hazardous crop. Therefore, all three human proteins will be expressed as follows: a) Develop recombinant DNA vectors for enhanced expression via tobacco chloroplast genomes b) generate transgenic plants c) characterize transgenic expression of proteins or fusion proteins using molecular and biochemical methods d) large scale purification of therapeutic proteins from transgenic tobacco and comparison of current purification/processing methods in E. coli or yeast e) Characterization and comparison of therapeutic proteins (yield, purity, functionality) produced in yeast or E. coli with transgenic tobacco f) animal testing and pre-clinical trials for effectiveness of the therapeutic proteins.

Mass production of affordable vaccines can be achieved by genetically engineering plants to produce recombinant proteins that are candidate vaccine antigens. The B subunits of Enteroxigenic E. coli (LTB) and cholera toxin of Vibrio cholerae (CTB) are examples of such antigens. When the native LTB gene was expressed via the tobacco nuclear genome, LTB accumulated at levels less than 0.01% of the total soluble leaf protein. Production of effective levels of LTB in plants, required extensive codon modification. Amplification of an unmodified CTB coding sequence in chloroplasts, up to 10,000 copies per cell, resulted in the accumulation of up to 4.1% of total soluble tobacco leaf protein as oligomers (about 410 fold higher expression levels than that of the unmodified LTB gene). PCR and Southern blot analyses confirmed stable integration of the CTB gene into the chloroplast genome. Western blot analysis showed that chloroplast synthesized CTB assembled into oligomers and was antigenically identical to purified native CTB. Also, GM.sub.1,-ganglioside binding assays confirmed that chloroplast synthesized CTB binds to the intestinal membrane receptor of cholera toxin, indicating correct folding and disulfide bond formation within the chloroplast. In contrast to stunted nuclear transgenic plants, chloroplast transgenic plants were morphologically indistinguishable from untransformed plants, when CTB was constitutively expressed. The introduced gene was stably inherited in the subsequent generation as confirmed by PCR and Southern blot analyses. Incrased production of an efficient transmucosal carrier molecule and delivery system, like CTB, in transgenic chloroplasts makes plant based oral vaccines and fusion proteins with CTB needing oral administration a much more practical approach.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:290101 USPATFULL

TITLE: Pharmaceutical proteins, human therapeutics, human serum albumin, insulin, native cholera toxic b submitted on transgenic plastids

INVENTOR(S): Daniell, Henry, Winter Park, FL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003204864	A1	20031030	
APPLICATION INFO.:	US 2001-807742	A1	20010418	(9)
	WO 2001-US6288		20010228	

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Schnader Harrison Segal & Lewis, IP Department 36th Floor, 1600 Market Street, Philadelphia, PA, 19103

NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 5552
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 14 USPATFULL on STN
TI Method of processing a proteinaceous material to recover K-casein macropeptide and polymers of a-lactalbumin and B-lactoglobulin
AB A method of processing a proteinaceous material that includes κ-casein macropeptide, the method entailing polymerizing protein present in the proteinaceous material to yield a proteinaceous intermediate, where the proteinaceous intermediate includes polymerized protein, and separating the proteinaceous intermediate to yield a first portion and a second portion, where the first portion includes a majority of the κ-casein macropeptide from the proteinaceous material and the second portion includes a majority of the polymerized protein from the proteinaceous intermediate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:238708 USPATFULL
TITLE: Method of processing a proteinaceous material to recover K-casein macropeptide and polymers of a-lactalbumin and B-lactoglobulin
INVENTOR(S): Brody, Ernest P., Minneapolis, MN, UNITED STATES
PATENT ASSIGNEE(S): Land O' Lakes, Inc., Arden Hills, MN, UNITED STATES, 55112 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003166866	A1	20030904	
APPLICATION INFO.:	US 2002-58907	A1	20020128	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KINNEY & LANGE, P.A., THE KINNEY & LANGE BUILDING, 312 SOUTH THIRD STREET, MINNEAPOLIS, MN, 55415-1002
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 4272
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 14 USPATFULL on STN
TI Polypeptides having L-asparaginase activity
AB Disclosed are polypeptides which originate from mammal, having L-asparaginase activity. The polypeptides are easily prepared by applying recombinant DNA techniques to DNAs encoding the polypeptides and they exert satisfactory effects in the treatment and/or the prevention for diseases caused by tumor cells dependent on L-asparagine, and cause no substantial serious side effects even when administered to humans in relatively-high dose.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:81452 USPATFULL
TITLE: Polypeptides having L-asparaginase activity
INVENTOR(S): Ario, Takeshi, Okayama, JAPAN
Taniai, Madoka, Okayama, JAPAN
Yamamoto, Kozo, Okayama, JAPAN
Kurimoto, Masashi, Okayama, JAPAN
PATENT ASSIGNEE(S): Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6537547	B1	20030325	
APPLICATION INFO.:	US 1997-869927		19970605	(8)

	NUMBER	DATE

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-168172	19960607

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Nashed, Nashaat T.
LEGAL REPRESENTATIVE: Browdy And Neimark
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 2434
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 14 USPATFULL on STN
TI Polypeptides having L-asparaginase activity
AB Disclosed are polypeptides which originate from mammal, having L-asparaginase activity. The polypeptides are easily prepared by applying recombinant DNA techniques to DNAs encoding the polypeptides and they exert satisfactory effects in the treatment and/or the prevention for diseases caused by tumor cells dependent on L-asparagine, and cause no substantial serious side effects even when administered to humans in relatively-high dose.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:209110 USPATFULL
TITLE: Polypeptides having L-asparaginase activity
INVENTOR(S): Ario, Takeshi, Okayama, JAPAN
Taniai, Madoka, Okayama, JAPAN
Yamamoto, Kozo, Okayama, JAPAN
Kurimoto, Masashi, Okayama, JAPAN
PATENT ASSIGNEE(S): Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6436396	B1	20020820
APPLICATION INFO.:	US 2000-634858		20000808 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-869927, filed on 5 Jun 1997

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-168172	19960607

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Nashed, Nashaat T.
LEGAL REPRESENTATIVE: Browdy and Neimark, P.L.L.C.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 2483
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 14 DGENE COPYRIGHT 2005 The Thomson Corp on STN
TI Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumour cells
AN AAY18042 peptide DGENE
AB This sequence represents the N-terminus of a fragment of the human multimeric **alpha-lactalbumin** (MAL). The invention relates to a method of producing a biologically active **oligomeric form** of **alpha-lactalbumin** (aLA) comprises oligomerising and stabilising aLA in the molten globule-like state. The oligomeric aLA is able to induce apoptosis in tumour cells and/or has a bactericidal effect not seen with monomeric aLA.
ACCESSION NUMBER: AAY18042 peptide DGENE
TITLE: Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumour cells
INVENTOR: Hakansson P A; Svanborg C; Svensson M W
PATENT ASSIGNEE: (HAKA-I)HAKANSSON P A.

(SVAN-I) SVANBORG C.
(SVEN-I) SVENSSON M W.
PATENT INFO: WO 9926979 A1 19990603 49
APPLICATION INFO: WO 1998-IB1919 19981123
PRIORITY INFO: GB 1998-12202 19980605
GB 1997-24725 19971121
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1999-357815 [30]
DESCRIPTION: Multimeric **alpha-lactalbumin** 30 kD protein N-terminal fragment.

L3 ANSWER 7 OF 14 DGENE COPYRIGHT 2005 The Thomson Corp on STN
TI Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumour cells
AN AAY18041 peptide DGENE
AB This sequence represents the N-terminus of a fragment of the human multimeric **alpha-lactalbumin** (MAL). The invention relates to a method of producing a biologically active **oligomeric form** of **alpha-lactalbumin** (aLA) comprises oligomerising and stabilising aLA in the molten globule-like state. The oligomeric aLA is able to induce apoptosis in tumour cells and/or has a bactericidal effect not seen with monomeric aLA.
ACCESSION NUMBER: AAY18041 peptide DGENE
TITLE: Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumour cells
INVENTOR: Hakansson P A; Svanborg C; Svensson M W
PATENT ASSIGNEE: (HAKA-I)HAKANSSON P A.
(SVAN-I) SVANBORG C.
(SVEN-I) SVENSSON M W.
PATENT INFO: WO 9926979 A1 19990603 49
APPLICATION INFO: WO 1998-IB1919 19981123
PRIORITY INFO: GB 1998-12202 19980605
GB 1997-24725 19971121
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1999-357815 [30]
DESCRIPTION: Multimeric **alpha-lactalbumin** 14 kD protein N-terminal fragment.

L3 ANSWER 8 OF 14 DGENE COPYRIGHT 2005 The Thomson Corp on STN
TI Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumour cells
AN AAY18040 peptide DGENE
AB This sequence represents the N-terminus of human **alpha-lactalbumin**. The invention relates to a method of producing a biologically active **oligomeric form** of **alpha-lactalbumin** (aLA) comprises oligomerising and stabilising aLA in the molten globule-like state. The oligomeric aLA is able to induce apoptosis in tumour cells and/or has a bactericidal effect not seen with monomeric aLA.
ACCESSION NUMBER: AAY18040 peptide DGENE
TITLE: Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumour cells
INVENTOR: Hakansson P A; Svanborg C; Svensson M W
PATENT ASSIGNEE: (HAKA-I)HAKANSSON P A.
(SVAN-I) SVANBORG C.
(SVEN-I) SVENSSON M W.
PATENT INFO: WO 9926979 A1 19990603 49
APPLICATION INFO: WO 1998-IB1919 19981123
PRIORITY INFO: GB 1998-12202 19980605
GB 1997-24725 19971121
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1999-357815 [30]
DESCRIPTION: Human **alpha-lactalbumin** N-terminal fragment.

L3 ANSWER 9 OF 14 DGENE COPYRIGHT 2005 The Thomson Corp on STN
TI Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumour cells
AN AAY18045 peptide DGENE
AB This sequence represents the N-terminus of a fragment of the human multimeric **alpha-lactalbumin** (MAL). The invention relates to a method of producing a biologically active **oligomeric form** of **alpha-lactalbumin** (aLA) comprises oligomerising and stabilising aLA in the molten globule-like state. The oligomeric aLA is able to induce apoptosis in tumour cells and/or has a bactericidal effect not seen with monomeric aLA.
ACCESSION NUMBER: AAY18045 peptide DGENE
TITLE: Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumour cells
INVENTOR: Hakansson P A; Svanborg C; Svensson M W
PATENT ASSIGNEE: (HAKA-I)HAKANSSON P A.
(SVAN-I) SVANBORG C.
(SVEN-I) SVENSSON M W.
PATENT INFO: WO 9926979 A1 19990603 49
APPLICATION INFO: WO 1998-IB1919 19981123
PRIORITY INFO: GB 1998-12202 19980605
GB 1997-24725 19971121
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1999-357815 [30]
DESCRIPTION: Multimeric **alpha-lactalbumin** protein N-terminal fragment.

L3 ANSWER 10 OF 14 DGENE COPYRIGHT 2005 The Thomson Corp on STN
TI Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumour cells
AN AAY18044 peptide DGENE
AB This sequence represents the N-terminus of a fragment of the human multimeric **alpha-lactalbumin** (MAL). The invention relates to a method of producing a biologically active **oligomeric form** of **alpha-lactalbumin** (aLA) comprises oligomerising and stabilising aLA in the molten globule-like state. The oligomeric aLA is able to induce apoptosis in tumour cells and/or has a bactericidal effect not seen with monomeric aLA.
ACCESSION NUMBER: AAY18044 peptide DGENE
TITLE: Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumour cells
INVENTOR: Hakansson P A; Svanborg C; Svensson M W
PATENT ASSIGNEE: (HAKA-I)HAKANSSON P A.
(SVAN-I) SVANBORG C.
(SVEN-I) SVENSSON M W.
PATENT INFO: WO 9926979 A1 19990603 49
APPLICATION INFO: WO 1998-IB1919 19981123
PRIORITY INFO: GB 1998-12202 19980605
GB 1997-24725 19971121
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1999-357815 [30]
DESCRIPTION: Multimeric **alpha-lactalbumin** 100 kD protein N-terminal fragment.

L3 ANSWER 11 OF 14 DGENE COPYRIGHT 2005 The Thomson Corp on STN
TI Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumour cells
AN AAY18043 peptide DGENE
AB This sequence represents the N-terminus of a fragment of the human multimeric **alpha-lactalbumin** (MAL). The invention relates to a method of producing a biologically active **oligomeric form** of **alpha-lactalbumin** (aLA) comprises oligomerising and stabilising aLA in the molten globule-like state. The oligomeric aLA is able to induce apoptosis in tumour cells and/or has a bactericidal effect not seen with monomeric aLA.
ACCESSION NUMBER: AAY18043 peptide DGENE

TITLE: Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumour cells
INVENTOR: Hakansson P A; Svanborg C; Svensson M W
PATENT ASSIGNEE: (HAKA-I) HAKANSSON P A.
(SVAN-I) SVANBORG C.
(SVEN-I) SVENSSON M W.
PATENT INFO: WO 9926979 A1 19990603 49
APPLICATION INFO: WO 1998-IB1919 19981123
PRIORITY INFO: GB 1998-12202 19980605
GB 1997-24725 19971121
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1999-357815 [30]
DESCRIPTION: Multimeric **alpha-lactalbumin** 60 kD protein N-terminal fragment.

L3 ANSWER 12 OF 14 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
TI An agent for transporting **alpha-lactalbumin** into cancer cells.
AN 1999-371026 [31] WPIDS
AB WO 9927967 A UPAB: 19990806
NOVELTY - An agent (A) comprising a protein complex comprising an **oligomeric form** of **alpha -lactalbumin** (MAL) and a further reagent (I), which is combined with MAL such that it is carried into the nucleoplasm of cells which are susceptible to MAL.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
(1) a method of treating cancer which comprises administering to cancer cells, a pharmaceutical composition (A) comprising a carrier or excipient; and
(2) a method of diagnosing cancer which method comprises applying to cells which are suspected of being cancerous, (A) and observing penetration of the agent into the nucleus of these cells.
USE - (A) is used in the treatment or in vitro diagnosis of cancer (claimed).
Dwg.0/0
ACCESSION NUMBER: 1999-371026 [31] WPIDS
DOC. NO. CPI: C1999-109521
TITLE: An agent for transporting **alpha-lactalbumin** into cancer cells.
DERWENT CLASS: B04 D16 K08
INVENTOR(S): HAKANSSON, P A; SVANBORG, C
PATENT ASSIGNEE(S): (HAKA-I) HAKANSSON P A; (SVAN-I) SVANBORG C
COUNTRY COUNT: 83
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9927967	A1	19990610	(199931)*	EN	48
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9911710	A	19990616	(199945)		
EP 1032426	A1	20000906	(200044)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
JP 2001524535	W	20011204	(200203)		48
US 6808930	B1	20041026	(200470)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9927967	A1	WO 1998-IB1920	19981123
AU 9911710	A	AU 1999-11710	19981123
EP 1032426	A1	EP 1998-954689	19981123

		WO 1998-IB1920	19981123
JP 2001524535	W	WO 1998-IB1920	19981123
		JP 2000-522952	19981123
US 6808930	B1	WO 1998-IB1920	19981123
		US 2000-555270	20000830

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9911710	A	Based on	WO 9927967
EP 1032426	A1	Based on	WO 9927967
JP 2001524535	W	Based on	WO 9927967
US 6808930	B1	Based on	WO 9927967

PRIORITY APPLN. INFO: GB 1997-25126 19971127

L3 ANSWER 13 OF 14 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
TI Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumor cells.
AN 1999-357815 [30] WPIDS
AB WO 9926979 A UPAB: 19990802
NOVELTY - A new method (M1) of producing a biologically active **oligomeric form** of **alpha -lactalbumin** (aLA) comprises oligomerising and stabilizing aLA in the molten globule-like state.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method for producing an **oligomeric form** of aLA which comprises exposing a source of aLA to an ion exchange medium which has been pre-treated with casein or an active component and recovering aLA in an **oligomeric form**;

(2) an ion exchange medium for use in the above methods, where the medium has been treated with casein or its active components;

(3) an ion exchange column comprising the ion exchange medium of (2); and

(4) an **oligomeric form** of aLA obtained by a method as in (M1) or (1).

USE - The oligomeric aLA is able to induce apoptosis in tumor cells and/or has a bactericidal effect not seen with monomeric aLA.

Dwg.0/8

ACCESSION NUMBER: 1999-357815 [30] WPIDS
DOC. NO. CPI: C1999-105891
TITLE: Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumor cells.
DERWENT CLASS: B04 D16
INVENTOR(S): HAKANSSON, P A; SVANBORG, C; SVENSSON, M W
PATENT ASSIGNEE(S): (HAKA-I) HAKANSSON P A; (SVAN-I) SVANBORG C; (SVEN-I) SVENSSON M W
COUNTRY COUNT: 83
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9926979	A1	19990603	(199930)*	EN	48
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9912541	A	19990615	(199944)		
EP 1032596	A1	20000906	(200044)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
JP 2001524491	W	20011204	(200203)		53

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9926979	A1	WO 1998-IB1919	19981123
AU 9912541	A	AU 1999-12541	19981123
EP 1032596	A1	EP 1998-955823	19981123
		WO 1998-IB1919	19981123
JP 2001524491	W	WO 1998-IB1919	19981123
		JP 2000-522135	19981123

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9912541	A	Based on	WO 9926979
EP 1032596	A1	Based on	WO 9926979
JP 2001524491	W	Based on	WO 9926979

PRIORITY APPLN. INFO: GB 1998-12202 19980605; GB 1997-24725 19971121

L3 ANSWER 14 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

TI Therapeutic agents.

AB An agent comprising a protein complex comprising an **oligomeric form** of **alpha-lactalbumin** (MAL) and a further reagent which is combined with MAL such that it is carried into the nucleoplasm of cells which are susceptible to MAL. Agents of the type, where the further reagent is a therapeutic or labelling reagent, can be used in diagnosis and therapy in particular of cancer.

ACCESSION NUMBER: 2005:12196 BIOSIS
DOCUMENT NUMBER: PREV200500019781
TITLE: Therapeutic agents.
AUTHOR(S): Svanborg, Catharina [Inventor, Reprint Author]; Hakansson, Per Anders [Inventor]
CORPORATE SOURCE: University of Lund Department of Laboratory Medicine, Division of Clinical Immunology, Solvegatan 23, S-223 62 Lund, Sweden
PATENT INFORMATION: US 6808930 October 26, 2004
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Oct 26 2004) Vol. 1287, No. 4. http://www.uspto.gov/web/menu/patdata.html. e-file. ISSN: 0098-1133 (ISSN print).
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 22 Dec 2004
Last Updated on STN: 22 Dec 2004

=> d his

(FILE 'HOME' ENTERED AT 16:42:54 ON 20 APR 2005)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 16:43:22 ON 20 APR 2005
L1 223 S ALPHA LACTOALBUMIN
L2 9177 S ALPHA LACTALBUMIN
L3 14 S L2 AND OLIGOMERIC FORM

=> s l2 and fatty acid
5 FILES SEARCHED...
L4 401 L2 AND FATTY ACID

=> s l4 and molten globule
L5 7 L4 AND MOLTEN GLOBULE

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 7 MEDLINE on STN
TI Conformation-dependent interaction of **alpha-lactalbumin** with model and biological membranes: a spin-label ESR study.
AB **Alpha-lactalbumin** (alpha-LA) is biosynthesized and stored at the smooth endoplasmic reticulum (ER), then transferred to the Golgi lumen when prolactin stimulation of lactose biosynthesis and secretion takes place. Because both environments are composed of membranes, it was of interest to examine the interactions of alpha-LA with relevant model and biological membranes. Using the ESR spin-labeled **fatty acid** analog 5-doxyl stearic acid, we found evidence reflecting the insertion of "acid-shocked" **molten globule** (MG) alpha-LA into lecithin or phosphatidylserine (PS) multi-lamellar vesicles. An additional approximately 3 G immobilization was observed in the alpha-LA-lecithin sample versus the lipid alone. With PS, the increased immobilization was almost 6 G, reflecting an enhanced effect caused by strong electrostatic interactions between the positively charged protein with the negatively charged headgroup at pH 2.4. This was also reflected in the broadening of the PS:alpha-LA phase transition. Additionally, we have demonstrated that alpha-LA in its apo-form also shows similar insertion characteristics with both model and natural lipid membranes. Upon addition of calcium, the apo-form is released from the membrane as the Ca(2+)-bound protein.
ACCESSION NUMBER: 2004216985 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15115187
TITLE: Conformation-dependent interaction of **alpha-lactalbumin** with model and biological membranes: a spin-label ESR study.
AUTHOR: Chaudhuri Dipankar; Narayan Mahesh; Berliner Lawrence J
CORPORATE SOURCE: Department of Chemistry & Biochemistry, University of Denver, 2190 E. Iliff Avenue, Denver, CO 80208-2436, USA.
CONTRACT NUMBER: GM 56970 (NIGMS)
SOURCE: Protein J, (2004 Jan) 23 (1) 95-101.
Journal code: 101212092. ISSN: 1572-3887.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200411
ENTRY DATE: Entered STN: 20040430
Last Updated on STN: 20041219
Entered Medline: 20041124

L5 ANSWER 2 OF 7 MEDLINE on STN
TI Lipids as cofactors in protein folding: stereo-specific lipid-protein interactions are required to form HAMLET (human **alpha-lactalbumin** made lethal to tumor cells).
AB Proteins can adjust their structure and function in response to shifting environments. Functional diversity is created not only by the sequence but by changes in tertiary structure. Here we present evidence that lipid cofactors may enable otherwise unstable protein folding variants to maintain their conformation and to form novel, biologically active complexes. We have identified unsaturated C18 fatty acids in the cis conformation as the cofactors that bind apo **alpha-lactalbumin** and form HAMLET (human **alpha-lactalbumin** made lethal to tumor cells). The complexes were formed on an ion exchange column, were stable in a **molten globule**-like conformation, and had attained the novel biological activity. The protein-**fatty acid** interaction was specific, as saturated C18 fatty acids, or unsaturated C18:1trans conformers were unable to form complexes with apo **alpha-lactalbumin**, as were fatty acids with shorter or longer carbon chains. Unsaturated cis fatty acids other than C18:1:9cis were able to form stable complexes, but these were not active in the apoptosis assay. The results demonstrate that stereo-specific lipid-protein interactions can stabilize partially unfolded conformations and form molecular complexes with novel biological activity. The results offer a new mechanism for the functional diversity of proteins, by exploiting lipids as essential, tissue-specific cofactors in this process.

ACCESSION NUMBER: 2003548969 MEDLINE
DOCUMENT NUMBER: PubMed ID: 14627740
TITLE: Lipids as cofactors in protein folding: stereo-specific lipid-protein interactions are required to form HAMLET (human **alpha-lactalbumin** made lethal to tumor cells).
AUTHOR: Svensson Malin; Mossberg Ann-Kristin; Pettersson Jenny; Linse Sara; Svanborg Catharina
CORPORATE SOURCE: Department of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, Lund, Sweden.
SOURCE: Protein science : a publication of the Protein Society, (2003 Dec) 12 (12) 2805-14.
Journal code: 9211750. ISSN: 0961-8368.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200407
ENTRY DATE: Entered STN: 20031121
Last Updated on STN: 20040715
Entered Medline: 20040714

L5 ANSWER 3 OF 7 USPATFULL on STN
TI Therapeutic agents
AB An agent comprising a protein complex comprising an oligomeric form of **alpha.-lactalbumin** (MAL) and a further reagent which is combined with MAL such that it is carried into the nucleoplasm of cells which are susceptible to MAL. Agents of the type, where the further reagent is a therapeutic or labelling reagent, can be used in diagnosis and therapy in particular of cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:270008 USPATFULL
TITLE: Therapeutic agents
INVENTOR(S): Svanborg, Catharina, University of Lund Department of Laboratory Medicine, Division of Clinical Immunology, Solvegatan 23, S-223 62 Lund, SWEDEN
Hakansson, Per Anders, Flormans gatan 2A, S-223 54 Lund, SWEDEN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6808930	B1	20041026	
	WO 9927967		19990610	
APPLICATION INFO.:	US 2000-555270		20000830	(9)
	WO 1998-IB1920		19981123	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-25126	19971127

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Caputa, Anthony C.
ASSISTANT EXAMINER: Holleran, Anne L.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1034
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 7 EMBASE on STN
TI Lipids as cofactors in protein folding: Stereo-specific lipid-protein interactions are required to form HAMLET (human .**alpha.-lactalbumin** made lethal to tumor cells).
AB Proteins can adjust their structure and function in response to shifting

environments. Functional diversity is created not only by the sequence but by changes in tertiary structure. Here we present evidence that lipid cofactors may enable otherwise unstable protein folding variants to maintain their conformation and to form novel, biologically active complexes. We have identified unsaturated C18 fatty acids in the cis conformation as the cofactors that bind apo .**alpha**.-**lactalbumin** and form HAMLET (human .**alpha**.-**lactalbumin** made lethal to tumor cells). The complexes were formed on an ion exchange column, were stable in a **molten globule**-like conformation, and had attained the novel biological activity. The protein-**fatty acid** interaction was specific, as saturated C 18 fatty acids, or unsaturated C18: 1trans conformers were unable to form complexes with apo .**alpha**.-**lactalbumin**, as were fatty acids with shorter or longer carbon chains. Unsaturated cis fatty acids other than C18:1:9cis were able to form stable complexes, but these were not active in the apoptosis assay. The results demonstrate that stereo-specific lipid-protein interactions can stabilize partially unfolded conformations and form molecular complexes with novel biological activity. The results offer a new mechanism for the functional diversity of proteins, by exploiting lipids as essential, tissue-specific cofactors in this process.

ACCESSION NUMBER: 2003479532 EMBASE
TITLE: Lipids as cofactors in protein folding: Stereo-specific lipid-protein interactions are required to form HAMLET (human .**alpha**.-**lactalbumin** made lethal to tumor cells).
AUTHOR: Svensson M.; Mossberg A.-K.; Pettersson J.; Linse S.; Svanborg C.
CORPORATE SOURCE: C. Svanborg, Dept. Microbiol./Immunol./Glycobiol., Institute of Laboratory Medicine, Lund University, Solvegatan 23, S-223 62 Lund, Sweden. Catharina.Svanborg@mig.lu.se
SOURCE: Protein Science, (2003) Vol. 12, No. 12, pp. 2805-2814. Refs: 30
ISSN: 0961-8368 CODEN: PRCIEI
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20031211
Last Updated on STN: 20031211

L5 ANSWER 5 OF 7 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
TI Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumor cells.
AN 1999-357815 [30] WPIDS
AB WO 9926979 A UPAB: 19990802
NOVELTY - A new method (M1) of producing a biologically active oligomeric form of **alpha** -**lactalbumin** (aLA) comprises oligomerising and stabilizing aLA in the **molten globule** -like state.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method for producing an oligomeric form of aLA which comprises exposing a source of aLA to an ion exchange medium which has been pre-treated with casein or an active component and recovering aLA in an oligomeric form;

(2) an ion exchange medium for use in the above methods, where the medium has been treated with casein or its active components;

(3) an ion exchange column comprising the ion exchange medium of (2); and

(4) an oligomeric form of aLA obtained by a method as in (M1) or (1).

USE - The oligomeric aLA is able to induce apoptosis in tumor cells and/or has a bactericidal effect not seen with monomeric aLA.

Dwg.0/8

ACCESSION NUMBER: 1999-357815 [30] WPIDS
DOC. NO. CPI: C1999-105891

TITLE: Production of oligomeric **alpha-lactalbumin** useful for inducing apoptosis in tumor cells.
DERWENT CLASS: B04 D16
INVENTOR(S): HAKANSSON, P A; SVANBORG, C; SVENSSON, M W
PATENT ASSIGNEE(S): (HAKA-I) HAKANSSON P A; (SVAN-I) SVANBORG C; (SVEN-I) SVENSSON M W
COUNTRY COUNT: 83
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9926979	A1	19990603	(199930)*	EN	48
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9912541	A	19990615	(199944)		
EP 1032596	A1	20000906	(200044)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
JP 2001524491	W	20011204	(200203)		53

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9926979	A1	WO 1998-IB1919	19981123
AU 9912541	A	AU 1999-12541	19981123
EP 1032596	A1	EP 1998-955823	19981123
		WO 1998-IB1919	19981123
JP 2001524491	W	WO 1998-IB1919	19981123
		JP 2000-522135	19981123

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9912541	A	Based on	WO 9926979
EP 1032596	A1	Based on	WO 9926979
JP 2001524491	W	Based on	WO 9926979

PRIORITY APPLN. INFO: GB 1998-12202 19980605; GB 1997-24725 19971121

L5 ANSWER 6 OF 7 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Conformation-dependent interaction of **alpha-lactalbumin** with model and biological membranes: A spin-label ESR study.
AB **alpha-Lactalbumin** (alpha-LA) is biosynthesized and stored at the smooth endoplasmic reticulum (ER), then transferred to the Golgi lumen when prolactin stimulation of lactose biosynthesis and secretion takes place. Because both environments are composed of membranes, it was of interest to examine the interactions of alpha-LA with relevant model and biological membranes. Using the ESR spin-labeled **fatty acid** analog 5-doxyl stearic acid, we found evidence reflecting the insertion of "acid-shocked" **molten globule** (MG) alpha-LA into lecithin or phosphatidylserine (PS) multi-lamellar vesicles. An additional apprx3 G immobilization was observed in the alpha-LA-lecithin sample versus the lipid alone. With PS, the increased immobilization was almost 6 G, reflecting an enhanced effect caused by strong electrostatic interactions between the positively charged protein with the negatively charged headgroup at pH 2.4. This was also reflected in the broadening of the PS:alpha-LA phase transition. Additionally, we have demonstrated that alpha-LA in its apo-form also shows similar insertion characteristics with both model and natural lipid membranes. Upon addition of calcium, the apo-form is released from the membrane as the Ca2+-bound protein.

ACCESSION NUMBER: 2004:237857 BIOSIS
DOCUMENT NUMBER: PREV200400237871
TITLE: Conformation-dependent interaction of **alpha-lactalbumin** with model and biological membranes: A spin-label ESR study.
AUTHOR(S): Chaudhuri, Dipankar [Reprint Author]; Narayan, Mahesh; Berliner, Lawrence J.
CORPORATE SOURCE: CD Strategies, 2250 Latham Street, Mountain View, CA, 94040, USA
berliner@du.edu
SOURCE: Protein Journal, (January 2004) Vol. 23, No. 1, pp. 95-101. print.
ISSN: 1572-3887 (ISSN print).
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 28 Apr 2004
Last Updated on STN: 28 Apr 2004

L5 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Lipids as cofactors in protein folding: Stereo-specific lipid-protein interactions are required to form HAMLET (human **alpha-lactalbumin** made lethal to tumor cells).
AB Proteins can adjust their structure and function in response to shifting environments. Functional diversity is created not only by the sequence but by changes in tertiary structure. Here we present evidence that lipid cofactors may enable otherwise unstable protein folding variants to maintain their conformation and to form novel, biologically active complexes. We have identified unsaturated C18 fatty acids in the cis conformation as the cofactors that bind apo **alpha-lactalbumin** and form HAMLET (human **alpha-lactalbumin** made lethal to tumor cells). The complexes were formed on an ion exchange column, were stable in a **molten globule**-like conformation, and had attained the novel biological activity. The protein-**fatty acid** interaction was specific, as saturated C18 fatty acids, or unsaturated C18:1trans conformers were unable to form complexes with apo **alpha-lactalbumin**, as were fatty acids with shorter or longer carbon chains. Unsaturated cis fatty acids other than C18:1:9cis were able to form stable complexes, but these were not active in the apoptosis assay. The results demonstrate that stereo-specific lipid-protein interactions can stabilize partially unfolded conformations and form molecular complexes with novel biological activity. The results offer a new mechanism for the functional diversity of proteins, by exploiting lipids as essential, tissue-specific cofactors in this process.
ACCESSION NUMBER: 2004:53432 BIOSIS
DOCUMENT NUMBER: PREV200400057124
TITLE: Lipids as cofactors in protein folding: Stereo-specific lipid-protein interactions are required to form HAMLET (human **alpha-lactalbumin** made lethal to tumor cells).
AUTHOR(S): Svensson, Malin; Mossberg, Ann-Kristin; Pettersson, Jenny; Linse, Sara; Svanborg, Catharina [Reprint Author]
CORPORATE SOURCE: Department of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, Solvegatan 23, S-223 62, Lund, Sweden
Catharina.Svanborg@mig.lu.se
SOURCE: Protein Science, (December 2003) Vol. 12, No. 12, pp. 2805-2814. print.
ISSN: 0961-8368.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 21 Jan 2004
Last Updated on STN: 21 Jan 2004

Refine Search

Search Results -

Terms	Documents
L12 and (EDTA)	5

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L13

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Wednesday, April 20, 2005 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L13	L12 and (EDTA)	5	L13
L12	L8 and (ion exchange)	83	L12
L11	l1 and l7	3	L11
L10	l7 and l6	1	L10
L9	L8 and l7	0	L9
L8	svensson.in.	813	L8
L7	hakansson.in.	127	L7
L6	svanborg.in.	5	L6
L5	L4 and (fatty acid or lipids)	109600	L5
L4	L3 and (molten globule-like state)	172400	L4
L3	L2 and (oligomeric form)	333723	L3
L2	alpha lactalbumin	369835	L2
L1	alpha lactalbumin	369835	L1

END OF SEARCH HISTORY

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 5 of 5 returned.

☐ 1. Document ID: US 6746568 B1

L13: Entry 1 of 5 File: USPT Jun 8, 2004

US-PAT-NO: 6746568
DOCUMENT-IDENTIFIER: US 6746568 B1

TITLE: Treatment of filtrates from peroxide bleaching of pulp

DATE-ISSUED: June 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Terelius; Hans	Uttran			SE
Olsson; Anette	Helsingborg			SE
Nilsson; Margareta	Helsingborg			SE
Svensson; Jessica	Helsingborg			SE
Rampotas; Christos	Helsingborg			SE

US-CL-CURRENT: 162/38; 162/41, 162/42, 162/43, 162/45, 162/60, 162/78, 162/79

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Ima

☐ 2. Document ID: US 6670378 B2

L13: Entry 2 of 5 File: USPT Dec 30, 2003

US-PAT-NO: 6670378
DOCUMENT-IDENTIFIER: US 6670378 B2
** See image for Certificate of Correction **

TITLE: Method of treating Parkinson's disease

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Svensson; Kjell A.	Portage	MI		

US-CL-CURRENT: 514/317

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Ima

☐ 3. Document ID: US 6653325 B2

L13: Entry 3 of 5 File: USPT Nov 25, 2003

US-PAT-NO: 6653325
DOCUMENT-IDENTIFIER: US 6653325 B2

** See image for Certificate of Correction **

TITLE: Method of treating parkinson's disease

DATE-ISSUED: November 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Svensson; Kjell A.	Portage	MI		

US-CL-CURRENT: 514/317

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Ima

---

☐ 4. Document ID: US 6290812 B1

L13: Entry 4 of 5 File: USPT Sep 18, 2001

US-PAT-NO: 6290812
DOCUMENT-IDENTIFIER: US 6290812 B1

TITLE: Method for treating process water in connection with pulp bleaching

DATE-ISSUED: September 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rampotas; Christos	Helsingborg			SE
Svensson; Viveka	Helsingborg			SE
Hansson; Jonny	Bjuv			SE
Nilsson; Margareta	Helsingborg			SE

US-CL-CURRENT: 162/29; 162/189, 162/DIG.8, 210/723, 210/912, 210/928

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Ima

---

☐ 5. Document ID: US 5866590 A

L13: Entry 5 of 5 File: USPT Feb 2, 1999

US-PAT-NO: 5866590
DOCUMENT-IDENTIFIER: US 5866590 A

TITLE: Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation

DATE-ISSUED: February 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Svensson; J.o slashed.rgen Ryhl	Frederikssund			DK
Nygaard; Lars	Valby			DK
Andersen; Tina Meinertz	Hoersholm			DK
Weibel; Helle	Hilleroed			DK
Hjorth; Thyge Borup	Farum			DK

US-CL-CURRENT: 514/326; 514/458, 514/474

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Ima

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L12 and (EDTA)	5

Display Format: CIT Change Format

Previous Page Next Page Go to Doc#

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 6808930 B1

L11: Entry 1 of 3 File: USPT Oct 26, 2004

US-PAT-NO: 6808930
DOCUMENT-IDENTIFIER: US 6808930 B1

TITLE: Therapeutic agents

DATE-ISSUED: October 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Svanborg; Catharina	Solvegatan 23, S-223 62 Lund			SE
	S-223 54 Lund			SE
Hakansson; Per Anders				

US-CL-CURRENT: 436/64; 424/1.37, 424/1.53, 424/1.65, 424/1.69, 424/130.1, 424/134.1, 424/135.1, 424/178.1, 424/182.1, 424/183.1, 424/9.1, 424/9.2, 436/63, 530/365, 530/366, 530/402

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Ima

☐ 2. Document ID: US 6681674 B2

L11: Entry 2 of 3 File: USPT Jan 27, 2004

US-PAT-NO: 6681674
DOCUMENT-IDENTIFIER: US 6681674 B2

TITLE: Band saw blade

DATE-ISSUED: January 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hakansson; William	SE-662 36 Amal			SE
Hakansson; Bengt Emanuel	SE-662 30 Amal			SE

US-CL-CURRENT: 83/661; 83/788, 83/835, 83/846, 83/853

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Ima

☐ 3. Document ID: US 6269792 B1

L11: Entry 3 of 3 File: USPT Aug 7, 2001

US-PAT-NO: 6269792
DOCUMENT-IDENTIFIER: US 6269792 B1

TITLE: Internal combustion engine with compressor function

DATE-ISSUED: August 7, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hakansson; Nils Olof	Stenkullen			SE

US-CL-CURRENT: 123/322

Terms	Documents
L1 and L7	3